---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-027245"
form_type: "8-K"
ticker: "NXGL"
cik: "0001468929"
company_name: "NEXGEL, INC."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:29:25.928379+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NexGel spins off drug delivery program into NexGelRx; shareholders get 19.99% equity stake

## Summary
- NEXGEL spins off select Rx drug delivery assets into new entity NexGelRx; retains 19.99% non-dilutive equity stake.
- NEXGEL will receive a 5% global royalty in perpetuity on products sold using its drug delivery technology.
- NexGelRx closed initial funding from outside investors; NEXGEL will be exclusive manufacturer of hydrogel for NexGelRx.
- Dr. Jerome Zeldis, NEXGEL director who helped bring 10 pharma products to market, will also serve on NexGelRx board.

## SEC filing metadata
- accession: 0001493152-25-027245
- form_type: 8-K
- ticker: NXGL
- cik: 0001468929
- company_name: NEXGEL, INC.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468929/000149315225027245/0001493152-25-027245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468929/000149315225027245/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-027245
- JSON: https://secwatch.observer/filing/0001493152-25-027245.json
- Plain text: https://secwatch.observer/filing/0001493152-25-027245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.